Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19490
Title: Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Adult,Aged,Aged, 80 and over,Antineoplastic Combined Chemotherapy Protocols/adverse,effects/*economics/*therapeutic use,Carcinoma, Squamous Cell/*drug therapy/*economics/mortality,Cost-Benefit Analysis,Deoxycytidine/administration & dosage/adverse effects/analogs &,derivatives/economics,Doxorubicin/administration & dosage/adverse effects/analogs &,derivatives/economics,Female,Greece,Head and Neck Neoplasms/*drug therapy/*economics/mortality,Humans,Male,Middle Aged,Paclitaxel/administration & dosage/adverse effects/economics,Patient Compliance/statistics & numerical data,Polyethylene Glycols/administration & dosage/adverse effects/economics,Survival Analysis,Treatment Outcome
URI: https://olympias.lib.uoi.gr/jspui/handle/123456789/19490
ISSN: 0923-7534
Link: http://www.ncbi.nlm.nih.gov/pubmed/16790517
http://annonc.oxfordjournals.org/content/17/10/1560.full.pdf
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Fountzilas-2006-Paclitaxel and gemci.pdf196.72 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons